Arterial Inflammation and E-Cigarettes

Study Purpose

Arterial inflammation will be compared using PET scanning in 3 groups: 1) Non-smokers, 2) Tobacco cigarette smokers, 3) Electronic cigarette users.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 21 Years - 45 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Nonsmokers OR.
  • - Daily e-cigarette user OR.
  • - Daily tobacco cigarette smoker.

Exclusion Criteria:

  • - Cardiac disease.
  • - Respiratory Disease.
- Diabetes mellitus

Trial Details

Trial ID:

This trial id was obtained from, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

University of California, Los Angeles
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Holly R Middlekauff, MD
Principal Investigator Affiliation University of California, Los Angeles
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries United States

The disease, disorder, syndrome, illness, or injury that is being studied.

Arterial Inflammation
Additional Details

Qualified participants will undergo a singe PET/CT to detect arterial inflammation.

Arms & Interventions


Other: Healthy control

Will undergo PET scan as a "negative control"

Other: Tobacco cigarette smoker

Will undergo PET scan as a "positive control"

Other: E-cigarette user

Will undergo PET scan


Other: - No drug or device, only a test. The test is called a PET/CT

A single PET/CT scan will be performed

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

UCaliforniaLA, Los Angeles, California





Los Angeles, California, 90095

Site Contact

Holly R Middlekauff, MD

[email protected]